UK MHRA Guidance: National Assessment Procedure for Medicines and Apply for a licence to Market a Medicine in the UK

Sharan Murugan
2 hours ago
3 min read

The UK medicines regulatory framework provides structured pathways for obtaining a licence to market a medicinal product. Two key guidance documents outline the National Assessment Procedure (NAP) and the process to Apply for a licence to market a medicine in the UK. Together, these resources explain how applicants can submit, manage, and progress marketing authorisation applications within the UK regulatory system.

Guidance: National Assessment Procedure (NAP) for Medicines

The National Assessment Procedure (NAP) is a regulatory pathway used when a marketing authorisation application is submitted directly to the UK regulator for assessment. This procedure is applicable when the product is intended to be authorised solely within the UK.

Under the NAP, the regulator conducts a full scientific assessment of the application, evaluating the quality, safety, and efficacy of the medicinal product. The procedure is structured with defined validation steps, assessment phases, and timelines.

Applicants must submit a complete dossier in the Common Technical Document (CTD) format, including administrative information, quality documentation, non-clinical data, clinical data, and proposed product information such as the Summary of Product Characteristics (SmPC), labelling, and package leaflet.

The National Assessment Procedure ensures that medicines supplied in the UK meet established regulatory standards and that benefit–risk balance is thoroughly evaluated prior to authorisation.

Key Features of the National Assessment Procedure

The NAP includes:

Validation of the submitted dossier to confirm completeness
Scientific assessment by multidisciplinary experts
Opportunities for applicants to respond to regulatory questions
Final decision based on overall benefit–risk evaluation

The process is designed to ensure regulatory consistency while providing applicants with a clear framework for submission and review.

Guidance: Applying for a Licence to Market a Medicine in the UK

To legally market a medicine in the UK, applicants must obtain a marketing authorisation (also referred to as a product licence). The guidance explains who can apply, what type of application may be required, and the documentation standards that must be met.

Applications may cover new active substances, generic medicines, hybrid applications, well-established use applications, biosimilars, or other recognised legal bases. The applicant must clearly define the legal basis for the application and provide supporting evidence accordingly.

The guidance also outlines administrative requirements, submission routes, and applicable fees. Applicants must ensure that their proposed product complies with UK regulatory standards, including pharmacovigilance obligations and manufacturing authorisation requirements.

Dossier Requirements and Submission Standards

Applicants are required to prepare and submit their application in electronic format, following CTD structure and technical standards. The submission must include:

Administrative and legal documentation
Quality (Chemistry, Manufacturing and Controls) data
Non-clinical pharmacology and toxicology data (where applicable)
Clinical efficacy and safety data
Risk management plans
Product information documents

Compliance with formatting and procedural requirements is essential to ensure timely validation and progression through the assessment process.

Regulatory Timelines and Interaction

The guidance explains that the regulator will review the application within defined timelines, which may vary depending on the type of procedure and complexity of the application. During assessment, applicants may receive requests for further information and are expected to respond within specified deadlines.

Clear communication and complete responses contribute to efficient progression toward a final decision.

Post-Authorisation Responsibilities

Once authorised, marketing authorisation holders must comply with ongoing regulatory obligations. These include pharmacovigilance reporting, management of variations, renewals, and ensuring that product information remains current.

Maintaining compliance throughout the product lifecycle is essential to preserve authorisation status and protect public health.

The UK’s National Assessment Procedure and marketing authorisation guidance provide a structured and transparent framework for licensing medicines. By defining submission standards, procedural steps, and scientific assessment criteria, the guidance ensures that medicines marketed in the UK meet established quality, safety, and efficacy standards.

Applicants planning to market a medicine in the UK should carefully review both guidance documents to ensure regulatory readiness and alignment with national requirements.